Ibogaine + MDA = “an extremely beneficial drug”?

#TBT to 1968 patents by Claudio Naranjo

“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”

1/12 Image
The patents claimed medical preparations of:

(1) ibogaine, iboga alkaloid extract, or total extract; plus

(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline

“The best results have been obtained with” MDA

The combination “forms an excellent medicine"

2/12 ImageImage
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”

3/12 Image
“The amphetamine derivative associated with the iboga extract, on the other hand, permits the emotional character necessary as complement to the stimulation of the mind and imagination as produced by the iboga to be restored to the patient.”

4/12 Image
“A toxicological study of the product has showed that secondary effects, e.g. vomiting & vertigo, are almost non-existent & that the medicine showed absolutely no danger as regards life or the biological balance of the invalid. The toxicity of this association is thus nil.”

5/12 Image
“In view of the extreme efficiency of the medicine, it seems pointless to visualise treatments of long duration.

The medicine, when used in psychotherapy, is in fact outstanding…at no time should the practician need to exceed 5 psychotherapy sessions…”

6/12 Image
“The spheres of application are immense.

Numerous clinical tests show that the medicine can be used in all diseases of psychosomatic character or of which the psychosomatic origin can be visualised.”

More than 50 cases were studied in psychiatry with 50 mental patients…”

7/12 Image
Case 1:

“A woman aged 35 years was treated for symptoms corresponding to an anxiety neurosis”

5 preparatory sessions, 3 drug sessions, “one or two interviews”

“Conclusion: No re-appearance of fears and a considerable improvement in the characterological difficulties."

8/12 ImageImage
Case 2:

“A woman aged 23 years attended bc of conflicts w her husband. She envisaged the possibility of divorce…before taking action, she decided to find out to what point her actual refusal to her husband could be the consequence of personal psychological difficulties.”

9/12 Image
Case 3:

“A man aged 30 years was affected by sexual troubles, homosexual tendency & sexual unsatisfaction in his conjugal life.

One treatment session which comprised a dosage of total extract of the iboga combined w MDA produced a substantial improvement to his problem.”

10/12 Image
“Pioneering psychedelic therapist” Claudio Naranjo:

“psychiatrist & pioneer in the integration of psychotherapy, spirituality, & psychedelic experiences”

“helped train MAPS’ first therapist team for MDMA-assisted psychotherapy for PTSD” in Spain

maps.org/news/posts/781…

11/12
First filed on January 31, 1968 in France, Naranjo’s application was eventually granted in France, Belgium, Germany, Canada, & the UK

worldwide.espacenet.com/patent/search/…

12/12 Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Graham Pechenik

Graham Pechenik Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @calyxlaw

20 Nov
Novel ketamine + psilocybin inventions?

New patent applications published:

𝔎 Celon Pharma—pulmonary administration of ketamine

𝔎 Univ Kansas—ketamine treatment for ALS

𝔎 Takeda Pharm—depression tx, after ketamine therapy

𝔎 CaaMTech—combinations of serotonergic drugs

1/6
Celon Pharma—“Ketamine Composition for Use in a Method of Treatment of Depression by Pulmonary Administration”

–inhalable dry powder ketamine compositions

–dosage regimens for their use “in a cycle of administrations of sequences of single doses”

appft.uspto.gov/netacgi/nph-Pa…

2/6 ImageImageImageImage
University of Kansas—“Ketamine Treatment for Amyotrophic Lateral Sclerosis”

Covers use of ketamine to:

–extend life expectancy

–increase number of days of survival

–reduce rate of deterioration of body weight

Claims all found novel & inventive

patentscope.wipo.int/search/en/deta…

3/6 ImageImageImageImage
Read 6 tweets
21 Mar
New Compass Pathways patents granted?

Another US patent was granted on March 16, 2021

This is Compass’ second US patent, in same family as the first patent granted on December 31, 2019

New ‘257 patent: patft.uspto.gov/netacgi/nph-Pa…

First ‘175 patent: patft.uspto.gov/netacgi/nph-Pa…

1/7
A primary difference between the new ‘257 & the first ‘175 patent is:

– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A

– ‘257 patent claims the “oral dosage form” itself

2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”

These are the peaks displayed when the polymorph is analyzed by X-ray

Compass unsuccessfully sought claims without these XRPD limitations

3/7
Read 7 tweets
20 Mar
Who will own psilocybin for anorexia?

One of the methods claimed in Compass’ PCT application is administering “a therapeutically-effective dose of psilocybin” to a subject with anorexia

Could a claim on treating anorexia with psilocybin be granted?

1/7
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia

This trial was first posted on December 10, 2020

2/7

clinicaltrials.gov/ct2/show/NCT04…
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx

This trial was posted earlier, on August 10, 2020

3/7

clinicaltrials.gov/ct2/show/NCT04…
Read 7 tweets
18 Feb
How much is a psilocybin patent application worth?

PharmaTher $PHRM sells psilocybin program to Revive Therapeutics $RVV

Includes full rights to PharmaTher’s psilocybin IP:

Pre-clinical work + three psilocybin provisional applications

1/4
Purchase price for PharmaTher’s psilocybin IP:

–$3 million in cash

–$4 million in securities

–up to $3 million in milestone payments

–“low single digit royalty” on future net sales

2/4
More on PharmaTher’s:

Psilocybin combination therapies:

Psilocybin in treatment of cancer:

Microneedle delivery technology, which it retains after the sale:

3/4
Read 4 tweets
17 Feb
“Emergency Off-Switch” for psychedelics?

MindMed $MMED beings study on “LSD neutralizer technology”

I.e., the 5-HT2A antagonist ketanserin: psychedelicreview.com/compound/ketan…

1/4
Patent application first announced on April 21, 2020

As @psyscireview subsequently wrote: “Few Details of the Invention Are Available”

18 months after filing, the application—& those details—will become public

~ October 2021

psychedelicreview.com/stopping-bad-l…

2/4
“LSD neutralizer technology”—is it possible, patentable, profitable?

Last year, from @D__Nickles: psymposia.com/magazine/rahn-…

Today, more insights from @mattbagg:

3/4
Read 4 tweets
16 Feb
Controlled release psilocybin + cannabinoid formulations?

New published patent application on multilayer tablets & capsules w psilocybe-derived + cannabis-derived compounds

Filed by Tassili Life Sciences, acquired last yr by Champignon Brands

patentscope.wipo.int/search/en/deta… $SHRM

1/ ImageImageImage
Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”

”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”

2/ Image
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”

"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”

3/ ImageImage
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Thank you for your support!

Follow Us on Twitter!

:(